8-K: Aflac Reports Strong Q3 Earnings, Boosts Dividend

Aflac Incorporated announced robust third-quarter 2025 results, with significant increases in net earnings and adjusted earnings per share, alongside a declared fourth-quarter dividend and substantial share repurchases.

Summary

• Total revenues for the third quarter of 2025 increased by 60.7% to $4.7 billion, primarily driven by net investment gains of $275 million compared to net investment losses of $1.4 billion in the prior year.
• Net earnings reached $1.6 billion, or $3.08 per diluted share, a substantial improvement from a net loss of $93 million, or $0.17 per diluted share, in the third quarter of 2024.
• Adjusted earnings for the quarter rose 9.6% to $1.3 billion, with adjusted earnings per diluted share increasing 15.3% to $2.49.
• Shareholders' equity stood at $28.7 billion, or $54.57 per share, at September 30, 2025, up 15.5% from $24.8 billion, or $44.60 per share, a year ago.
• The annualized return on average shareholders' equity in the third quarter was 23.5%.
• Aflac Japan's pretax adjusted earnings in yen increased 13.1% to 179.5 billion yen, with total new annualized premium sales up 11.8% to 19.6 billion yen, driven by strong sales of the Miraito cancer insurance product.
• Aflac U.S. net earned premiums increased 2.5% to $1.5 billion, and sales rose 2.8% to $390 million, primarily from group life and disability products.
• The board of directors declared a fourth-quarter dividend of $0.58 per share, payable on December 1, 2025.
• Aflac repurchased $1.0 billion of its common shares (9.3 million shares) in the third quarter, with 121.6 million shares remaining authorized for repurchase.
• The total net impact from the Q3 assumption update increased EPS by $0.76.
• In the U.S. business, a one-time contract termination fee of $21 million was booked as part of a strategic technology plan to optimize efficiencies and migrate to the cloud.

Sentiment

Score: 9

Explanation: The company reported exceptionally strong net earnings, significant growth in adjusted earnings per share, robust sales in both key markets, and a strong capital position. The commitment to shareholder returns through increased dividends and substantial share repurchases further enhances positive sentiment, despite some investment-related losses and a one-time expense.

Positives

• Net earnings surged to $1.6 billion from a net loss of $93 million year-over-year, representing a 1,862.4% increase.
• Adjusted earnings per diluted share increased 15.3% to $2.49, with no impact from foreign exchange rates.
• Total revenues grew 60.7% to $4.7 billion, largely due to a shift from net investment losses to gains.
• Aflac Japan reported a 13.1% increase in pretax adjusted earnings in yen terms and an 11.8% increase in new annualized premium sales, driven by the Miraito cancer insurance product.
• Aflac U.S. net earned premiums increased 2.5%, supported by strong persistency of 79.0% and a 2.8% increase in sales, particularly in group life and disability products.
• The company declared a fourth-quarter dividend of $0.58 per share, marking 43 consecutive years of dividend increases.
• A significant $1.0 billion was deployed for share repurchases in the quarter, demonstrating strong capital return to shareholders.
• Capital ratios remain robust, with an SMR above 900%, estimated regulatory ESR above 250%, and estimated combined RBC greater than 600%.
• Adjusted book value per share excluding foreign currency remeasurement increased 6.3% to $46.35.
• The pretax adjusted profit margin for Aflac Japan improved significantly to 52.2% from 44.7% a year ago, primarily due to reserve remeasurement gains.
• The pretax adjusted profit margin for Aflac U.S. increased to 21.7% from 20.8%.

Negatives

• Aflac Japan's net earned premiums in yen terms declined 4.0%, mainly due to internal cancer reinsurance transactions.
• For the first nine months of 2025, total revenues were down 9.1% to $12.3 billion compared to $13.5 billion in 2024.
• Net earnings for the first nine months of 2025 were $2.3 billion, a 36.0% decrease from $3.5 billion in the same period of 2024.
• A one-time contract termination fee of $21 million was incurred in the U.S. segment due to early termination of a services contract as part of a technology migration plan.
• Increased CECL reserves for the commercial real estate portfolio by $28 million and for middle market loans by $7 million, reflecting continued distressed property values.
• U.S. statutory recorded a $7 million valuation allowance on mortgage loans as an unrealized loss.
• Japan FSA reported securities impairments of 476 million yen and a net realized loss of 189 million yen related to transitional real estate loans.

Risks

• Difficult conditions in global capital markets and the economy, including inflation.
• Defaults and credit downgrades of investments.
• Global fluctuations in interest rates and exposure to significant interest rate risk.
• Concentration of business in Japan and limited availability of acceptable yen-denominated investments.
• Foreign currency fluctuations in the yen/dollar exchange rate.
• Differing interpretations applied to investment valuations and significant valuation judgments in determination of expected credit losses.
• Decreases in financial strength or debt ratings and decline in creditworthiness of other financial institutions.
• Ability to attract and retain qualified sales associates, brokers, employees, and distribution partners.
• Deviations in actual experience from pricing and reserving assumptions.
• Ability to continue to develop and implement improvements in information technology systems and execute revenue growth and expense management initiatives.
• Interruption in telecommunication, information technology and other operational systems, or a failure to maintain security, confidentiality, integrity or privacy of sensitive data, including the impact of the June 2025 network incident.
• Subsidiaries' ability to pay dividends to the Parent Company.
• Inherent limitations to risk management policies and procedures and operational risks of third-party vendors.
• Changes in tax rates applicable to the Company.
• Failure to comply with restrictions on policyholder privacy and information security.
• Extensive regulation and changes in law or regulation by governmental authorities.
• Competitive environment and ability to anticipate and respond to market trends.
• Catastrophic events, including those related to climate change, epidemics, pandemics, natural disasters, war, public health issues, terrorism, or other acts of violence.
• Ability to protect the Aflac brand and the Company's reputation.
• Ability to effectively manage key executive succession.
• Changes in accounting standards.
• Level and outcome of litigation or regulatory inquiries.
• Allegations or determinations of worker misclassification in the United States.

Future Outlook

For 2025, Aflac Japan's underlying earned premiums are expected to decline by 1% to 2%, with a benefit ratio in the 58% to 60% range and an expense ratio at the lower end of 20% to 23%. Its pretax profit margin is projected to be in the 35% to 38% range. Aflac U.S. expects its benefit ratio to be at the lower end of 48% to 52% and its expense ratio in the mid to upper end of 36% to 39% as new business lines scale. The U.S. pretax profit margin is anticipated to be at the upper end of the 17% to 20% range.

Management Comments

• "Aflac delivered very solid earnings for the quarter and the first nine months. These results reflect our focused efforts to execute on our strategy of creating long-term value for shareholders." Daniel P. Amos, Chairman and CEO.
• "I am pleased with Aflac Japan's 11.8% year-over-year sales increase in the quarter and ongoing strong premium persistency. The strong sales were driven largely by continued sales of our cancer insurance product Miraito, which was launched in March." Daniel P. Amos, Chairman and CEO.
• "In the U.S., I am pleased with our 2.5% increase in net earned premiums, which is supported by our strong persistency of 79% and a 2.8% increase in sales in the quarter." Daniel P. Amos, Chairman and CEO.
• "We continue to generate strong capital and cash flows while maintaining our commitment to prudent liquidity and capital management." Daniel P. Amos, Chairman and CEO.
• "Especially as we celebrate Aflac's 70th anniversary this month, we treasure our 2025 milestone of 43 consecutive years of dividend increases and remain committed to extending this record, supported by our financial strength." Daniel P. Amos, Chairman and CEO.
• "Adjusted earnings per diluted share increased 15.3% year over year to $2.49, with no impact from FX in the quarter." Max K. Brodn, Senior Executive Vice President and CFO.
• "Overall, we view these results in the quarter as very good." Max K. Brodn, Senior Executive Vice President and CFO.
• "We anticipate reduced costs and improved efficiency, which will offset the termination fee over the next few years." Max K. Brodn, Senior Executive Vice President and CFO.

Industry Context

Aflac's strong performance, particularly in Japan with new cancer insurance products like Miraito and in the U.S. with group life and disability, demonstrates successful product innovation and adaptation to evolving customer needs. The company's focus on 'third sector protection' in Japan and scaling new business lines in the U.S. aligns with broader industry trends towards specialized and comprehensive insurance solutions. The emphasis on prudent expense management and maintaining strong pretax margins indicates a strategic focus on efficiency and profitability in a competitive global insurance market.

Comparison to Industry Standards

• Aflac is recognized as the No. 1 provider of supplemental health insurance products in the U.S., according to the LIMRA 2024 U.S. Supplemental Health Insurance Total Market Report.
• Aflac Life Insurance Japan is the leading provider of cancer and medical insurance in Japan in terms of policies in force.
• The company has been included in the World's Most Ethical Companies by Ethisphere for 19 consecutive years (2025), indicating strong corporate governance and ethical practices compared to peers.
• Aflac has been recognized as one of Fortune's World's Most Admired Companies for 24 years (2025), reflecting high regard within the industry and among stakeholders.
• The company's commitment to 43 consecutive years of dividend increases positions it as a reliable dividend growth stock, a benchmark for long-term investor value.
• Aflac became a signatory of the Principles for Responsible Investment (PRI) in 2021 and has been included in the Dow Jones Sustainability North America Index (2024) for 11 years, demonstrating leadership in sustainability and responsible investment practices.

Stakeholder Impact

• Shareholders benefit from significantly improved net earnings, increased adjusted earnings per share, a declared dividend increase, and substantial share repurchases, indicating strong returns and commitment to long-term value.
• Policyholders and customers in Japan benefit from new product offerings like Miraito cancer insurance and a continued focus on third sector protection, while U.S. customers see growth in group life and disability products.
• Employees and sales associates are impacted by the company's ability to attract and retain qualified personnel, which is identified as a risk factor.
• Creditors and rating agencies are positively impacted by the company's strong capital ratios, prudent liquidity management, and leverage within target ranges.

Next Steps

• Aflac Incorporated will webcast its quarterly conference call on November 5, 2025, at 8:00 a.m. (ET).
• The company intends to continue its balanced approach of investing in growth and driving long-term operating efficiencies.
• Aflac remains committed to extending its record of 43 consecutive years of dividend increases.

Key Dates

Recommendation

Aflac's Q3 2025 results demonstrate exceptional financial performance, with a dramatic turnaround in net earnings and robust growth in adjusted earnings per share. The company's strategic initiatives in both Japan and the U.S. are yielding positive sales results, particularly with new product introductions. Strong capital management, evidenced by significant share repurchases and a continued commitment to dividend increases, underscores a shareholder-friendly approach. While there are some investment-related losses and a one-time expense, the overall financial health, strong capital ratios, and positive outlook make Aflac a compelling 'strong buy' for investors seeking stable growth and consistent returns.

Keywords

Aflac, Insurance, Supplemental Health Insurance, Cancer Insurance, Financial Results, Earnings, Dividends, Share Repurchase, Japan Insurance, U.S. Insurance, Financial Services, Investment Income, Adjusted Earnings, Capital Management, Risk Management